GB0303319D0 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
GB0303319D0
GB0303319D0 GBGB0303319.8A GB0303319A GB0303319D0 GB 0303319 D0 GB0303319 D0 GB 0303319D0 GB 0303319 A GB0303319 A GB 0303319A GB 0303319 D0 GB0303319 D0 GB 0303319D0
Authority
GB
United Kingdom
Prior art keywords
organic compounds
compounds
gsk
pkc
lymphocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0303319.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to GBGB0303319.8A priority Critical patent/GB0303319D0/en
Publication of GB0303319D0 publication Critical patent/GB0303319D0/en
Priority to JP2005518422A priority patent/JP2006515004A/ja
Priority to CA002513613A priority patent/CA2513613A1/en
Priority to EP04710393A priority patent/EP1597250B8/en
Priority to EP09004073A priority patent/EP2075249B1/en
Priority to CNB2004800029076A priority patent/CN100439359C/zh
Priority to DE602004026415T priority patent/DE602004026415D1/de
Priority to US10/542,175 priority patent/US7820672B2/en
Priority to ES09004073T priority patent/ES2385071T3/es
Priority to PT04710393T priority patent/PT1597250E/pt
Priority to AT04710393T priority patent/ATE463491T1/de
Priority to PCT/EP2004/001323 priority patent/WO2004072062A2/en
Priority to AT09004073T priority patent/ATE551335T1/de
Priority to ES04710393T priority patent/ES2343115T3/es
Priority to BRPI0407512-9A priority patent/BRPI0407512A/pt
Priority to JP2009165725A priority patent/JP2009280592A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
GBGB0303319.8A 2003-02-13 2003-02-13 Organic compounds Ceased GB0303319D0 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
GBGB0303319.8A GB0303319D0 (en) 2003-02-13 2003-02-13 Organic compounds
BRPI0407512-9A BRPI0407512A (pt) 2003-02-13 2004-02-12 derivados de indolilmaleimida
DE602004026415T DE602004026415D1 (de) 2003-02-13 2004-02-12 Indolylmaleimid derivate
ES09004073T ES2385071T3 (es) 2003-02-13 2004-02-12 Derivados de indolilmaleimida
EP04710393A EP1597250B8 (en) 2003-02-13 2004-02-12 Indolylmaleimide derivatives
EP09004073A EP2075249B1 (en) 2003-02-13 2004-02-12 Indolylmaleimide derivatives
CNB2004800029076A CN100439359C (zh) 2003-02-13 2004-02-12 吲哚基马来酰亚胺衍生物
JP2005518422A JP2006515004A (ja) 2003-02-13 2004-02-12 インドリルマレイミド誘導体
US10/542,175 US7820672B2 (en) 2003-02-13 2004-02-12 Indolylmaleimide derivatives
CA002513613A CA2513613A1 (en) 2003-02-13 2004-02-12 Indolylmaleimide derivatives
PT04710393T PT1597250E (pt) 2003-02-13 2004-02-12 Derivados indolilmaleimida
AT04710393T ATE463491T1 (de) 2003-02-13 2004-02-12 Indolylmaleimid derivate
PCT/EP2004/001323 WO2004072062A2 (en) 2003-02-13 2004-02-12 Indolylmaleimide derivatives
AT09004073T ATE551335T1 (de) 2003-02-13 2004-02-12 Indolylmaleimid-derivate
ES04710393T ES2343115T3 (es) 2003-02-13 2004-02-12 Derivados de indolilmaleimida.
JP2009165725A JP2009280592A (ja) 2003-02-13 2009-07-14 インドリルマレイミド誘導体

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0303319.8A GB0303319D0 (en) 2003-02-13 2003-02-13 Organic compounds

Publications (1)

Publication Number Publication Date
GB0303319D0 true GB0303319D0 (en) 2003-03-19

Family

ID=9952961

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0303319.8A Ceased GB0303319D0 (en) 2003-02-13 2003-02-13 Organic compounds

Country Status (12)

Country Link
US (1) US7820672B2 (https=)
EP (2) EP1597250B8 (https=)
JP (2) JP2006515004A (https=)
CN (1) CN100439359C (https=)
AT (2) ATE463491T1 (https=)
BR (1) BRPI0407512A (https=)
CA (1) CA2513613A1 (https=)
DE (1) DE602004026415D1 (https=)
ES (2) ES2385071T3 (https=)
GB (1) GB0303319D0 (https=)
PT (1) PT1597250E (https=)
WO (1) WO2004072062A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006268908A1 (en) 2005-07-11 2007-01-18 Novartis Ag Indolylmaleimide derivatives
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
ES2410955T3 (es) 2006-12-19 2013-07-04 Novartis Ag Derivados de indolilmaleimida como inhibidores de la quinasa
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN101671329B (zh) * 2009-06-17 2012-11-07 东华大学 3-氨基醇取代的吲哚马来酰亚胺化合物、其制备和应用
JP2016504299A (ja) 2012-12-10 2016-02-12 セントジーン アーゲー 白血病を予防および治療するためのマレイミド誘導体の使用
CN104693198B (zh) * 2014-12-13 2017-03-08 浙江工业大学 3‑(1,2,4‑三氮唑并[4,3‑a]吡啶‑3‑基)‑4‑(1H‑吲哚‑3‑基)马来酰亚胺类衍生物及其制备方法和应用
CA2984794A1 (en) 2015-05-07 2016-11-10 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
IL299072A (en) 2015-12-02 2023-02-01 Memorial Sloan Kettering Cancer Center Antibodies and methods for using them
MA46770A (fr) 2016-11-09 2019-09-18 Agenus Inc Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
WO2018132636A1 (en) * 2017-01-12 2018-07-19 The Research Foundation For The State University Of New York [18f]maleimide-based glycogen synthase kinase-3beta ligands for positron emission tomography imaging and radiosynthesis method
CN110551103B (zh) * 2018-05-30 2022-08-23 北京大学深圳研究生院 一种jak3选择性抑制剂
EP3920885A1 (en) 2019-02-08 2021-12-15 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0629947B2 (ja) 1986-07-16 1994-04-20 正浩 入江 光学記録材料
CZ280738B6 (cs) 1988-02-10 1996-04-17 F. Hoffmann - La Roche And Co., Aktiengesellschaft Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
DE4005970A1 (de) 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
GB9123396D0 (en) 1991-11-04 1991-12-18 Hoffmann La Roche A process for the manufacture of substituted maleimides
WO1993018765A1 (en) 1992-03-20 1993-09-30 The Wellcome Foundation Limited Indole derivatives with antiviral activity
JPH06161024A (ja) 1992-11-26 1994-06-07 Sanyo Electric Co Ltd 光学記録材料
US5405864A (en) * 1993-10-15 1995-04-11 Syntex (U.S.A.) Inc. Chemotherapeutic maleimides
US5559228A (en) * 1995-03-30 1996-09-24 Eli Lilly And Company Synthesis of bisindolylmaleimides
JPH0961647A (ja) 1995-08-25 1997-03-07 Nippon Telegr & Teleph Corp <Ntt> 光素子用有機材料
FR2772266B1 (fr) 1997-12-12 2000-02-04 Oreal Utilisation d'agent de coloration photochrome dans une composition cosmetique, et composition cosmetique le comprenant
ATE284387T1 (de) 1998-10-08 2004-12-15 Smithkline Beecham Plc 3-(3-chloro-4-hydroxyphenylamino)-4-(2- nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3)
GB9828640D0 (en) 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds
DE10042603B4 (de) 1999-08-31 2010-04-29 Kyocera Corp. Photochrome Verbindung und ihre Verwendung in optischen Funktionsvorrichtungen
WO2001030331A2 (en) 1999-10-22 2001-05-03 Eli Lilly And Company Therapeutic compositions including protein kinase c inhibitors
US6281356B1 (en) 1999-12-22 2001-08-28 Hoffmann-La Roche Inc. Substituted pyrroles
MXPA02011079A (es) 2000-05-11 2004-08-19 Consejo Superior Investigacion Inhibidores heterociclicos de quinasa de sintasa de glucogeno gsk3.
YU4403A (sh) 2000-07-27 2006-05-25 F. Hoffmann-La Roche Ag. Derivati 3-indolil-4-fenil-1h-pirol-2,5-diona, kao inhibitori glikogen sintaza kinaze-3 beta
AU2002221810B2 (en) * 2000-11-07 2005-06-23 Novartis Ag Indolylmaleimide derivatives as protein kinase C inhibitors
JP2002285146A (ja) 2001-03-27 2002-10-03 Masahiro Irie フォトクロミック組成物及び線量計
AU2002249103A1 (en) 2001-03-29 2002-10-15 Topo Target Aps Succinimide and maleimide derivatives and their use as topoisomerase ii catalytic inhibitors
BE1014306A6 (fr) 2001-07-19 2003-08-05 Project 21C Dispositif de stationnement d'un cycle avec antivol.
MXPA04008671A (es) * 2002-03-08 2004-12-06 Lilly Co Eli Derivados de pirrol-2,5-diona y su uso como inhibidores de gsk-3.
PE20040079A1 (es) * 2002-04-03 2004-04-19 Novartis Ag Derivados de indolilmaleimida

Also Published As

Publication number Publication date
CN1742005A (zh) 2006-03-01
DE602004026415D1 (de) 2010-05-20
JP2006515004A (ja) 2006-05-18
EP1597250B1 (en) 2010-04-07
CN100439359C (zh) 2008-12-03
EP2075249A3 (en) 2009-09-02
EP2075249B1 (en) 2012-03-28
ATE551335T1 (de) 2012-04-15
JP2009280592A (ja) 2009-12-03
CA2513613A1 (en) 2004-08-26
PT1597250E (pt) 2010-06-25
US20060058356A1 (en) 2006-03-16
EP2075249A2 (en) 2009-07-01
BRPI0407512A (pt) 2006-02-14
EP1597250A2 (en) 2005-11-23
US7820672B2 (en) 2010-10-26
WO2004072062A3 (en) 2004-11-04
ATE463491T1 (de) 2010-04-15
ES2343115T3 (es) 2010-07-23
ES2385071T3 (es) 2012-07-17
EP1597250B8 (en) 2010-05-19
WO2004072062A2 (en) 2004-08-26

Similar Documents

Publication Publication Date Title
GB0303319D0 (en) Organic compounds
ECSP12006206A (es) Inhibidores de quinasa p38 basados en heterociclos de 5 miembros.
IL175055A0 (en) Combinations useful for the treatment of neuronal disorders
TW200608979A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
TW200612910A (en) Medicaments comprising carbonyl compounds, and the use thereof
MXPA05009595A (es) Compuestos 7-amino-isoindolilo y sus usos farmaceuticos.
IL176581A0 (en) Immunomodulatory compounds for the treatment of central nervous system disorders
NO20053211D0 (no) Forbindelser for behandling av metabolske forstyrrelser.
PT1696905E (pt) 2-aminotetralinas substituídas para o tratamento preventivo da doença de parkinson
GB2418025B (en) Device for the prevention or treatment of ulcers
ATE534391T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen
GB0329874D0 (en) Compounds useful for the treatment of diseases
GB0416508D0 (en) Therapeutic agents
PL1900362T3 (pl) Pochodne alfa-aminoamidu użyteczne w leczeniu zaburzeń uzależnieniowych
BRPI0509660A (pt) compostos de beta-carbolina de utilidade no tratamento de doenças inflamatórias
PT1492501E (pt) Métodos de uso de corpos lamelares para propósitos terapêuticos
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
GB0410238D0 (en) Therapeutic agents
GB2388027B (en) Use of palatinose for the treatment of mental stress
PL1612210T3 (pl) Nowe analogi nitrobenzylotioinozyny
ZA200803101B (en) 4-oxadiozolyl-piperidine compounds and use thereof
TW200613301A (en) Novel amino-halogen-imidazopyridines
ZA200407501B (en) &#34;The treatment of sludge&#34;.
UA87851C2 (ru) Производные пирролотриазина, применимые для лечения гиперпролиферативных нарушений и заболеваний, связанных с ангиогенезом

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)